Meeting
2015 ASCO Annual Meeting
A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM).
Authors
Kent C. Shih
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN
Kent C. Shih , Sajeel A. Chowdhary , Kevin P. Becker , Joachim M. Baehring , William H. Liggett , Howard A. Burris III, John D. Hainsworth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT01349660
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2065)
DOI
10.1200/jco.2015.33.15_suppl.2065
Abstract #
2065
Poster Bd #
54
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.
First Author: Patrick Y. Wen
Poster
2022 ASCO Annual Meeting
Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1 inhibitor) in combination with bevacizumab and hypofractionated radiotherapy for recurrent glioblastoma: NCT03532295.
First Author: Jian Li Campian
Poster
2021 ASCO Annual Meeting
Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
First Author: Manmeet Singh Ahluwalia
Poster
2020 ASCO Virtual Scientific Program
Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.
First Author: Jaleh Fallah